PureTech Health eyes Nasdaq listing for ADS

Clinical-stage biotherapeutics company PureTech Health has filed a public registration statement to the US Securities and Exchange Commission as it looks to list its American depository shares on the Nasdaq.

PureTech stated that in light of its "strong cash position", the potential US listing would not include the issuance or offering of any shares.

Following the listing, PureTech's American depository shares will trade on the Nasdaq Global Market, providing access for investors who prefer US-listed stocks.

However, the FTSE 250-listed firm added that it intends to maintain its premium listing on the Official List of the UK Financial Conduct Authority and trading on the main market of the London Stock Exchange.

As of 0915 GMT, PureTech shares were down 0.60% at 250.50p.